Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alpha amylase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Alpha amylase. Displaying page 1 of 1.
    EudraCT Number: 2010-024262-22 Sponsor Protocol Number: CML-V Start Date*: 2012-08-24
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini...
    Medical condition: chronic phase CML
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001802-32 Sponsor Protocol Number: C1501 Start Date*: 2015-08-14
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: Neuronal correlates of Neurexan® action in mildly to moderately stressed probands - a randomized, placebo-controlled, double-blind, cross-over trial of mode of action and response prediction by fun...
    Medical condition: mildly to moderately stressed probands
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001901-18 Sponsor Protocol Number: LGS.MMR.01.2016.2022 Start Date*: 2017-02-14
    Sponsor Name:The Danish National University Hospital "Rigshospitalet"
    Full Title: Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting
    Medical condition: Infection with measles, mumps or rubella
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036654 Prevention LLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-008715-26 Sponsor Protocol Number: CA182037 Start Date*: 2009-08-05
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carci...
    Medical condition: intermediate stage hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003652-20 Sponsor Protocol Number: Ptcl-01501 Start Date*: 2013-12-04
    Sponsor Name:D-Pharm Ltd.
    Full Title: Pilot trial of intravenous DP-b99 in the treatment of first-ever episode of non-obstructive acute high-risk pancreatitis
    Medical condition: Acute pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10000971 Acute pancreatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004591-35 Sponsor Protocol Number: ADVL1211 Start Date*: 2018-12-14
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP)
    Full Title: A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Patients with relapsed or refractory solid tumors including CNS tumors and malignant melanoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-004285-53 Sponsor Protocol Number: VA 2008/28 Start Date*: 2008-12-19
    Sponsor Name:Centre Régional de Lutte contre le Cancer Val d'Aurelle- Paul Lamarque
    Full Title: Etude de phase I-II évaluant l’association Sorafénib (NEXAVAR®) et Irinotecan en deuxième ligne ou plus de traitement des cancers colorectaux métastatiques avec une mutation de Kras – NEXIRI
    Medical condition: Cancer du côlon ou du rectum métastatique prouvé histologiquement
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001879-43 Sponsor Protocol Number: B9991005 Start Date*: 2016-03-11
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 1b/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Either Crizotinib or PF-06463922 in Pa...
    Medical condition: Anaplastic Lymphoma Kinase (ALK) (negative and positive) Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10025051 Lung cancer non-small cell stage II LLT
    18.1 100000004864 10025052 Lung cancer non-small cell stage III LLT
    18.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 17:44:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA